BIIB021 (mesylate)

BIIB021 (CNF2024) mesylate is the mesylate of BIIB021 (HY-10212) . BIIB021 is an orally active Hsp90 inhibitor. BIIB021 inhibits the proliferation of chronic myeloid leukemia (CML) cells, with IC50 values of K562, K562/G, 32Dp210, and 32Dp210-T315I cells are 513.99, 603.53, 110.08, and 148.07 nM, respectively. BIIB021 degrades BCR-ABL protein and inhibits the β-catenin/c-Myc pathway. BIIB021 can also induce autophagy in CML cells. BIIB021 can be used for the research of CML[1].

Product Specifications

CAS Number

[1225041-97-3]

Product Name Alternative

CNF2024 (mesylate)

UNSPSC

12352005

Target

Autophagy; c-Myc; HSP; β-catenin

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Stem Cell/Wnt

Field of Research

Cancer

Smiles

O=S(O)(C)=O.ClC1=NC(N)=NC2=C1N=CN2CC3=NC=C(C)C(OC)=C3C

Molecular Formula

C15H19ClN6O4S

Molecular Weight

414.87

References & Citations

[1]He W, et al. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells. Int J Oncol. 2016 Apr;48 (4) :1710-20.